PLSE vs. NARI, NVST, PRCT, IRTC, WRBY, LIVN, ENOV, NVCR, TMDX, and LMAT
Should you be buying Pulse Biosciences stock or one of its competitors? The main competitors of Pulse Biosciences include Inari Medical (NARI), Envista (NVST), PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), TransMedics Group (TMDX), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.
Pulse Biosciences vs.
Inari Medical (NASDAQ:NARI) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking.
91.0% of Inari Medical shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by insiders. Comparatively, 71.5% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Inari Medical has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.
Pulse Biosciences received 181 more outperform votes than Inari Medical when rated by MarketBeat users. Likewise, 63.66% of users gave Pulse Biosciences an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.
In the previous week, Inari Medical had 6 more articles in the media than Pulse Biosciences. MarketBeat recorded 8 mentions for Inari Medical and 2 mentions for Pulse Biosciences. Inari Medical's average media sentiment score of 0.43 beat Pulse Biosciences' score of 0.34 indicating that Inari Medical is being referred to more favorably in the media.
Pulse Biosciences has a net margin of 0.00% compared to Inari Medical's net margin of -13.68%. Inari Medical's return on equity of -10.09% beat Pulse Biosciences' return on equity.
Inari Medical has higher revenue and earnings than Pulse Biosciences.
Inari Medical presently has a consensus price target of $68.00, indicating a potential downside of 14.97%. Given Inari Medical's stronger consensus rating and higher possible upside, analysts clearly believe Inari Medical is more favorable than Pulse Biosciences.
Summary
Inari Medical beats Pulse Biosciences on 10 of the 16 factors compared between the two stocks.
Get Pulse Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pulse Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:PLSE) was last updated on 2/23/2025 by MarketBeat.com Staff
Free PLSE Stock Alerts